Literature DB >> 22405659

Cardiac magnetic resonance imaging for stage B heart failure.

Sara L Partington1, Susan Cheng, João A C Lima.   

Abstract

Cardiac magnetic resonance imaging (CMR) can play a key role in the assessment and follow-up of patients with stage B heart failure. CMR currently serves as the reference standard for quantifying right and left ventricular size and ejection fraction. Technical advances have also enabled CMR to provide noninvasive tissue characterization and detailed assessments of myocardial performance. Thus, in addition to standard metrics of cardiac structure and function, CMR offers a variety of tools for determining cause, severity, and estimating the prognosis associated with an asymptomatic cardiomyopathy.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22405659     DOI: 10.1016/j.hfc.2011.11.009

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  2 in total

Review 1.  Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Authors:  Saro H Armenian; Melissa M Hudson; Renee L Mulder; Ming Hui Chen; Louis S Constine; Mary Dwyer; Paul C Nathan; Wim J E Tissing; Sadhna Shankar; Elske Sieswerda; Rod Skinner; Julia Steinberger; Elvira C van Dalen; Helena van der Pal; W Hamish Wallace; Gill Levitt; Leontien C M Kremer
Journal:  Lancet Oncol       Date:  2015-03       Impact factor: 41.316

2.  Left Ventricular Function and Myocardial Triglyceride Content on 3T Cardiac MR Predict Major Cardiovascular Adverse Events and Readmission in Patients Hospitalized with Acute Heart Failure.

Authors:  Kuang-Fu Chang; Gigin Lin; Pei-Ching Huang; Yu-Hsiang Juan; Chao-Hung Wang; Shang-Yueh Tsai; Yu-Ching Lin; Ming-Ting Wu; Pen-An Liao; Lan-Yan Yang; Min-Hui Liu; Yu-Chun Lin; Jiun-Jie Wang; Koon-Kwan Ng; Shu-Hang Ng
Journal:  J Clin Med       Date:  2020-01-08       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.